Arousal Cream 1 (Aminophylline / Ergoloid Mesylate /Pentoxifylline / Sildenafil Citrate / Testosterone / L-Arginine) (30 mL)30 / 0.5 / 50 / 10 / 1 / 60 mg/mL

Compounded from a admixture of tradition products, Thrill Cream is designed to act locally without substantial immersion into the bloodstream. This synergistic drug draws upon the parcels of each component( one bronchodilator, four vasodilators, and the potent coitus steroid hormone testosterone) that may give womanish libido( coitus drive) and sexual stimulation improvement. Aminophylline Theophylline is a xanthine outgrowth that’s used both orally or intravenously in the treatment of apnea of punctuality and as an peripheral agent for cases with asthma. While theophylline was generally used to treat asthma in the history, its use is much less common moment because there are effective druthers with better safety biographies. Oral theophylline is n’t recommended for asthma conservation remedy in children lower than 12 times. In adolescents and grown-ups, low- cure sustained- release oral theophylline is considered an alternate, but not preferred, remedy to the use of gobbled corticosteroids( ICSs) or may be used as an alternate, spare treatment to ICS in those with patient asthma symptoms. Intravenous aminophylline and theophylline are n’t recommended for the operation of acute asthma exacerbations because they appear to give no fresh benefit to optimal gobbled beta2- agonist remedy and may increase threat of adverse goods. There’s antithetical substantiation regarding the effectiveness of low- cure theophylline on exacerbation rates in habitual obstructive pulmonary complaint( COPD); in general, the medicine has a moderate bronchodilator effect that may affect in an cumulative but mild enhancement in FEV1 when added to beta- agonists. The threat for theophylline toxin increases at tablets that produce remedial benefit. Theophylline and aminophylline are n’t recommended for the routine treatment of COPD and should n’t be used in acute COPD exacerbations due to the low efficacity at recommended boluses and the eventuality for adverse responses and toxin. Theophylline is also approved for the treatment of apnea of punctuality in babes; still, it’s generally a alternate- line treatment option after caffeine due to its narrow remedial window for serum attention. Theophylline has been used off- marker for the operation of renal impairment and facilitation of extubation in babes, the forestallment of apnea during prostaglandin E1 infusion, and the treatment of methotrexate toxin. Aminophylline, apro-drug of theophylline, is the form constantly used for IV remedy. Because 100 mg of aminophylline is original to 80 mg of theophylline, crimes in dosing are possible, and clinicians should precisely assess lozenge adaptations and computations when switching between aminophylline and theophylline. Practice guidelines do n’t support the use of ergoloid mesylates in the treatment of Alzheimer’s complaint. Unlike these agents, pentoxifylline has hematological goods that are useful in the characteristic treatment of complications of supplemental vascular conditions. Sildenafil originally developed for the treatment of pulmonary hypertension, angina, and other cardiovascular conditions, sildenafil citrate was accidentally set up to be salutary in males who suffered from erectile dysfunction( ED). Prior to the discovery of its benefits in treating ED, this condition was considered to be an ineluctable part of growing in men or due to underpinning cerebral causes. After its blessing in 1998 by the U.S. Other contributing factors to its appeal and fashionability are that sildenafil citrate can be taken orally on demand and is generally well permitted with minimum adverse goods. Sildenafil citrate is a vasoactive drug belonging to the medicine class of phosphodiesterase – 5 enzyme( PDE- 5) impediments; it’s a competitive antagonist of this enzyme. PDE- 5 can be set up each over the mortal body, especially in the corpus cavernosum within the penis, striated and smooth musculature, as well as in platelets. still, PDE- 5 has the largest distribution in the penile corpus cavernosum which is why sildenafil citrate is suitable to work widely in this part of the body.

Arousal Cream is designed to enhance blood flow to specific areas of the body, especially the female genitalia. It contains four active ingredients known as vasodilators, which help relax blood vessels and allow them to widen. When blood vessels expand, more blood pools in the peripheral areas like veins, which reduces pressure on the heart and improves circulation throughout the body. This mechanism is commonly used in medicines for heart diseases, migraines, and wound healing. In Arousal Cream, the same principle helps increase blood flow to the vaginal area during stimulation, potentially improving sexual function and arousal.

It’s often used in asthma treatment because it helps open airways and reduce inflammation. Interestingly, it also stimulates the central nervous system, making it useful for certain sleep-related breathing problems.

Ergoloid mesylates are believed to enhance brain function, although their exact mechanism isn’t fully understood. Scientists think they may improve oxygen delivery and support nerve cell metabolism, possibly helping with memory and mental clarity.

This helps blood flow better through smaller vessels and improves oxygen delivery. It’s sometimes used in conditions like sickle cell anemia or peripheral artery disease, where blood flow is compromised.

Sildenafil, more popularly known for treating erectile dysfunction, helps maintain erections by preventing the breakdown of a natural chemical called cGMP. It also helps with lung circulation and has been studied as a treatment option for pulmonary hypertension.

It’s also used in treating rare conditions where the body can’t properly eliminate nitrogen waste, and it helps lower blood ammonia levels.

Finally, testosterone is a crucial hormone for sexual development and overall health. It starts influencing the body even before birth and plays a role throughout life. Testosterone helps build muscle, shape body fat, support bone strength, and regulate sexual function. It’s also involved in controlling energy, mood, and even how the body processes calcium and glucose.

Together, these ingredients in Arousal Cream work in harmony to boost blood flow, relax muscles, and support sexual health, making it a unique product designed to address intimate wellness while also offering broader benefits like improved circulation and tissue health.

Arousal Cream Contraindications and Precautions
General Precautions

Before using Arousal Cream, especially if you have contraindications with intercourse or underlying medical conditions, consult your healthcare provider. Do not use this cream if you are allergic to any ingredients, have a history of genital herpes, chronic vaginal infections, or serious medical conditions such as heart disease or autoimmune disorders. Despite primarily acting locally, the contraindications for each active compound may apply, so inform your physician about your medical conditions and current medications before use.

Active Ingredient Contraindications and Warnings
Aminophylline

May alter lab test results such as glucose, uric acid, and cortisol levels.

Requires careful monitoring in patients with cardiac disease, thyroid disorders, and respiratory issues.

Clearance is reduced in hepatic disease, hypothyroidism, sepsis, and shock.

Elderly, neonates, and patients with renal impairment need lower doses and close monitoring.

Smoking and fever can affect drug clearance.

Not proven teratogenic but should be used cautiously in pregnancy and breastfeeding.

Ergoloid Mesylate

Avoid in patients with sensitivity to ergot derivatives and those with psychosis.

Use cautiously in bradycardia, hypotension, or hepatic disease.

Avoid in breastfeeding due to unknown risks and interference with lactation.

Contraindicated in pregnancy due to uterine stimulant effects.

Considered inappropriate for elderly patients according to Beers Criteria.

Pentoxifylline

Requires monitoring in renal impairment, bleeding disorders, and elderly patients.

Classified as pregnancy category C; use cautiously with monitoring.

Excreted in breast milk; consider discontinuation or alternative therapy.

Sildenafil

Avoid in patients with hypersensitivity, those on nitrate therapy, or with significant cardiac issues.

Associated with potential severe hypotension and myocardial infarction when combined with nitrates.

Arginine

Contraindicated in hypersensitive individuals and in patients with renal or hepatic impairment.

Can cause electrolyte imbalances and hyperkalemia; monitor closely.

Pregnancy category B; use cautiously due to insufficient human data.

Breastfeeding effects unknown; consider risk vs. benefit.

Extreme caution advised in pediatric patients due to risk of metabolic acidosis and cerebral edema.

Testosterone

Requires monitoring for cardiovascular events and prostate health.

Not recommended for elderly patients without established safety data.

Pregnancy category X; contraindicated in women and breastfeeding mothers.

Use cautiously in patients with hepatic, renal, or cardiac diseases.

Associated with serious adverse reactions such as pulmonary oil microembolism and anaphylaxis; available through restricted programs.

Important Safety Information About Arousal Cream and Its Ingredients

Arousal Cream contains six active ingredients that work together in ways that are not fully studied. Each ingredient has its own interactions with other medicines, supplements, or health conditions. When combined, these effects may be stronger or different from what we expect. For this reason, it’s very important that you share a complete list of everything you’re taking with your healthcare provider. You should also let them know if you smoke, drink alcohol, or use recreational drugs, as these can further affect how the cream works.

Some ingredients to be aware of:

Arginine: This amino acid may slightly increase the levels of certain pain-relief medicines like aspirin or acetaminophen by affecting how your kidneys process them. It may also interact with antacids like aluminum or magnesium compounds, which can neutralize urine acidity, potentially affecting how other drugs are absorbed.

Testosterone: This hormone can interact with many medicines. It may increase the risk of bleeding when taken with blood thinners like warfarin, and it can affect blood sugar levels in people with diabetes. It may also cause fluid retention, especially if combined with steroids like prednisone. Some medications, like fluconazole, may increase testosterone levels in the body. Others, like antiandrogen drugs or certain herbal supplements like saw palmetto, may block testosterone’s effects.

General precautions: Testosterone is processed by liver enzymes, and some drugs may either increase or decrease its effectiveness. For example, it can interfere with medicines for heart disease, raise the chance of liver damage, and even affect how your body responds to other treatments. In some cases, it may also stimulate red blood cell production, leading to higher blood thickness, which can be dangerous.

These are only a few examples, and interactions may vary depending on your health and other medications you use. Some of these interactions may not cause problems in all people, but they can lead to serious side effects in others.

Because of these risks, always inform your healthcare provider about all the products you are taking and any health issues you may have. They can help you decide whether Arousal Cream is right for you and how to use it safely. Don’t start, stop, or change the way you take any medication without professional guidance. Monitoring may be required to avoid complications, especially when combining treatments that affect your heart, blood pressure, hormones, or kidneys.

Ultimately, being open and transparent with your healthcare provider ensures the best possible care and helps you avoid unintended side effects while achieving the benefits you’re seeking from Arousal Cream.

Important Information About Arousal Cream and Its Ingredients

Arousal Cream is designed to increase blood flow to the area where it’s applied, helping to enhance sensitivity and improve the experience of orgasm. However, it’s important to understand that the cream itself does not directly cause an orgasm. If not fully absorbed, it may cause irritation for your partner during intimacy.

The cream is formulated to work locally on the skin, so side effects are usually minimal. Some people may experience skin irritation, headaches, dizziness, or feelings of restlessness. But because it contains multiple active ingredients, it’s possible that other side effects could occur, even those not yet studied when the ingredients are combined. For this reason, you should always tell your healthcare provider about all the medicines, supplements, or other substances you are using. You should also share details about smoking, drinking alcohol, or using recreational drugs, as these can affect how the cream works.

What to watch for:
Call your doctor right away if you experience signs of an allergic reaction, such as skin rash, itching, hives, swelling of the face, lips, or tongue, difficulty breathing, chest pain, or dizziness. These symptoms can be serious and require immediate medical attention.

Specific ingredient information:

• Aminophylline: This ingredient can cause stomach upset, nausea, vomiting, or diarrhea, especially when first starting treatment. It may also cause caffeine-like effects such as headaches, insomnia, or anxiety. In rare cases, severe reactions like seizures or heart problems can occur, especially in older adults or those with underlying conditions.

• Ergoloid Mesylate: This can cause nausea, vomiting, stomach cramps, and reduced appetite. It may lower blood pressure, causing dizziness or fainting. Monitoring your blood pressure and heart rate during treatment is recommended.

• Pentoxifylline: Common side effects include nausea, vomiting, bloating, or indigestion. If these occur, your doctor may adjust your dosage. Rarely, issues like dry mouth or constipation may occur.

General precautions:
Some ingredients, such as testosterone, can interact with other drugs, including blood thinners, steroids, or medications for diabetes, potentially leading to increased risks like bleeding or changes in blood sugar. Other compounds like aminophylline or ergoloid mesylate may have effects on the heart, nervous system, or gastrointestinal tract, especially when taken in combination or at high doses.

Bottom line:
Always consult with your healthcare provider before using Arousal Cream, especially if you are on other medications or have preexisting conditions. Monitoring for side effects and adjusting treatment as needed is crucial to staying safe. The ingredients work together in ways that are not fully understood, so it’s better to be cautious and proactive in protecting your health.

Important Precautions for Pregnancy and Breastfeeding

Arousal Cream is not recommended for use during pregnancy or if you are trying to become pregnant. One of its ingredients, testosterone, is classified as highly risky (FDA pregnancy category X) because it can cause serious harm to a developing fetus. However, there is an alternative version of the cream available that does not contain testosterone.

During Pregnancy:

• Aminophylline (and theophylline): These are sometimes used for asthma treatment in pregnant women, but they are not the preferred choice. There’s limited research on their safety during pregnancy, and using them may increase the risk of toxicity in newborns. If doctors decide they are necessary, close monitoring of blood levels is required to ensure safety.

• Ergoloid Mesylate: There isn’t enough information about its safety in pregnancy, but other related substances are known to cause uterine contractions or harm the fetus. Because of this, it’s generally avoided during pregnancy.

• Pentoxifylline: Classified as pregnancy category C, meaning there’s no conclusive evidence about its safety. It should only be used when the potential benefits outweigh the risks.

• Sildenafil: This drug is considered safer (category B), as studies haven’t shown birth defects or miscarriages. However, there’s not enough information to confirm its effects on breast milk.

• Arginine: Also considered category B, with no evidence of harm in animals, but human studies are lacking. Experts advise against its use during pregnancy.

• Testosterone: Strongly contraindicated (category X) due to expected harm to the fetus. Women of childbearing age using this ingredient must use reliable contraception.

During Breastfeeding:

• Aminophylline: It passes into breast milk in amounts similar to what’s in the mother’s blood. It can cause irritability or other mild side effects in infants but is unlikely to cause serious harm unless the mother’s levels are dangerously high.

• Ergoloid Mesylate: Other related substances are known to pass into breast milk and cause symptoms like vomiting or seizures in nursing infants. Therefore, it’s best avoided during breastfeeding.

• Pentoxifylline: It is present in breast milk and has been linked to risks in animals. Although infants are likely exposed to small amounts, caution is advised, and breastfeeding decisions should be made carefully.

• Sildenafil: There’s insufficient data on its presence in breast milk or potential effects on nursing infants, so caution is recommended.

• Arginine: It’s unclear whether it enters breast milk, but systemically administered amino acids are generally considered safe in small amounts. However, risks should still be weighed.

• Testosterone: Strongly discouraged during breastfeeding as it may interfere with milk production and could have harmful effects on the infant’s development.

Store this medication at 68°F to 77°F (20°C to 25°C) and away from heat, moisture and light. Keep all medicine out of the reach of children. Throw away any unused medicine after the beyond use date. Do not flush unused medications or pour down a sink or drain.

1. Barnes PJ. Theophylline: new perspectives for an old drug. Am J Respir Crit Care Med. 2003;167:813-818.
2. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2020. Available from: http://www.ginasthma.org.– LinkOpens in New Tab Accessed May 20th, 2020.
3. Expert Panel Working Group of the National Heart, Lung, and Blood Institute (NHLBI) administered and coordinated National Asthma Education and Prevention Program Coordinating Committee (NAEPPCC), et al. 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. J Allergy Clin Immunol. 2020;146:1217-1270.
4. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2021. Retrieved 3/8/2021. Available on the World Wide Web at https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf– LinkOpens in New Tab
5. Bernini JC, Fort DW, Griener JC, et al. Aminophylline for methotrexate-induced neurotoxicity. Lancet 1995;345:544-7.
6. Lynch BA, Gal P, Ransom JL, et al. Low-dose aminophylline for the treatment of neonatal non-oliguric renal failure – case series and review of the literature. J Pediatr Pharmacol Ther 2008;13:80-7.
7. Hochwald C, Kennedy K, Chang J, Moya F. A randomized, controlled, double-blind trial comparing two loading doses of aminophylline. J Perinatol 2002; 22:275-278.
8. Lim DS, Kulik TJ, Kim DW, et al. Aminophylline for the prevention of apnea during prostaglandin E1 infusion. Pediatrics 2003; 112: e22.
9. Dalabih A, Harris ZL, Bondi SA, Arnold DH. Contemporary aminophylline use for status asthmaticus in pediatric ICUs. Chest 2012; 141: 1122-3.
10. Thompson TL 2nd, Filley CM, Mitchell WD, et al. Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 1990;323:445-448.
11. Schneider LS, Olin JT. Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787-798.
12. Doody RS, Stevens JC, Beck C, et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurol 2001;56:1154-1166.
13. Olin J, Schneider L, Novit A, et al. Hydergine for dementia. Cochrane Database Syst Rev. 2001;(2):CD000359.
14. O’Brien JT, Holmes C, Jones M, et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. J Psychopharmacol 2017;31:147-168.
15. Brucki SMD, Ferraz AC, de Freitas GR, et al. Treatment of vascular dementia. Recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. Dement Neuropsychol 2011;5:275-87.
16. Rabins PV, Rovner BW, Rummans T, et al. American Psychiatric Association Guideline watch (October 2014): practice guideline for the treatment of patients with Alzheimer’s disease and other dementias. 2014:1-26.
17. Dennenhoffer MA, Rozek S. Pentoxifylline in sickle cell anemia. Drug Intel Clin Pharm 1987;21:620.
18. Vinik AI, Holland MT, Le Beau JM, et al. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
19. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Card 1997;80:331-333.
20. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med 1996;334:1380-8.
21. Persson CGA. Overview of effects of theophylline. J Allergy Clin Immunol 1986;78:780-7.
22. Javaheri S, Parker TJ, Wexler L, et al. Effect of theophylline on sleep-disordered breathing in heart failure. N Engl J Med 1996;335:562-7.
23. Hollister LE, Yesavage J. Ergoloid mesylates for senile dementias. Unanswered questions. Ann Intern Med 1984;100:894-898.
24. Ergoloid mesylates tablet package insert. Cranbury, NJ: Sun Pharmaceuticals, Inc.: 2017 Nov.
25. Arginine hydrochloride injection (R-GENE) package insert. Lake Forest, IL: Hospira Inc.; 2010 Jan.
26. Ammonul (sodium phenylacetate and sodium benzoate) injection package insert. Scottsdale, AZ: Ucyclyd Pharma Inc.; 2011 Jul
27. Summar M. Current strategies for the management of neonatal urea cycle disorders. J Pediatr 2001; 138: S30-S39.
28. Batshaw, ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138:S46-S55
29. Adrogue HJ, Madias NE: Management of life-threatening acid-base disorders. Second of two parts. N Eng J Med 1998;338:107-11.
30. Bode-Boger SM, Boger RH, Galland A. L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol 1998; 46: 489-497.
31. Tangphao O, Grossmann M, Chalon S, et al. Pharmacokinetics of intravenous and oral L-arginine in normal volunteers. Br J Clin Pharmacol 1999; 47: 261-266.
32. Aminophylline (aminophylline dihydrate) package insert. Lake Forest, IL: Hopsira, Inc.; 2009 Nov.
33. Elixophyllin (theophylline, anhydrous) liquid package insert. Detroit, MI: Caraco Pharmaceutical Laboratories, Inc.; 2010 Feb.
34. Theophylline extended-release (theophylline, anhydrous) tablet package insert. Pomona, NY: Pliva, Inc.; 2007 Feb.
35. Theophylline injection package insert. Lake Forest, IL: Hospira, Inc.; 2008 July.
36. NAEPP Working Group Report on Managing Asthma During Pregnancy. Recommendations for Pharmacologic Treatment-Update 2004. NIH Publication No. 05-3279. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 2004
37. Hardy-Fairbanks AJ, Baker ER. Asthma in pregnancy: pathophysiology, diagnosis and management. Obstet Gynecol Clin North Am. 2010;37:159-172.
38. Giles W, Murphy V. Asthma in pregnancy: a review. Obstet Med. 2013;6:58-63. Epub 2013 May 3. Review.
39. Uniphyl (theophylline, anhydrous) tablets package insert. Stamford, CT: Purdue Pharmaceutical Products LP; 2004 Mar.
40. Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
41. D.H.E 45 (dihydroergotamine) injection package insert. Costa Mesa, CA: Valeant Pharmaceuticals North America; 2007 Nov.
42. Sansert (methysergide) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2000 Feb.
43. Cafergot (caffeine; ergotamine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2002 June.
44. Knowles JA. Excretion of drugs in milk-a review. J Pediatr 1965;66:1068-82.
45. American Academy of Pediatrics (AAP) Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics 2001;108(3):776-789.
46. Nappi C, Colace G, Di Carlo C, et al. Effect of dihydroergocryptine on serum prolactin levels and milk secretion in puerperal women. Gynecol Endocrinol 1993;7:129-33.
47. Tamura T, Satoh T, Minakami H, et al. Effect of hydergine in hyperprolactinemia. J Clin Endocrinol Metab 1989;69:470-4.
48. Raymond GV. Teratogen update: ergot and ergotamine. Teratology 1995;51:344-7.
49. The American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;00:1-21.
50. Pentoxifylline (Trental) tablets package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; Oct 2007.
51. Witter FR, Smith RV. The excretion of pentoxifylline and its metabolites into human breast milk. Am J Obstet Gynecol. 1985;151:1094-7.
52. Bushinsky DA, Gennari J. Life-threatening hyperkalemia induced by arginine. Annals of Internal Medicine 1978; 89: 632-634.
53. FDA: Arginine hydrochloride injection (marketed as R-Gene 10). FDA Drug Safety Newsletter 2009;2(2):16-18.
54. DELATESTRYL (Testosterone Enanthate Injection, USP) package insert. Lexington, MA: Indevus Pharmaceuticals, Inc.; 2007 July.
55. Axiron (testosterone) topical solution, package insert. Indianapolis, IN: Lilly USA, LLC; 2011 Dec.
56. The American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012;60:616-31.
57. Vigen R, O’Donnell CI, Baron AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
58. WD Finkle, S Greenland, GK Ridgeway, et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. DOI: 10.1371/journal.pone.0085805
59. FDA Medwatch – FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. Retrieved January 31, 2014. Available on the World Wide Web https://www.fda.gov/Drugs/DrugSafety/ucm383904.htm– LinkOpens in New Tab
60. (testosterone gel) package insert. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2010 Apr.
61. Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2014 Jun.
62. Androgel (testosterone gel) package insert. Marietta, GA: Solvay Pharmaceuticals, Inc.; 2012 Sept.
63. Striant (testosterone buccal system) package insert. Livingston, NJ: Columbia Laboratories, Inc.; 2014 Mar.
64. Fortesta (testosterone) gel, package insert. Chadds Ford, PA: Endo Pharmaceuticals Inc.; 2010 Dec.
65. Aveed (testosterone undecanoate Injection) package insert. Malvern, PA: Endo Pharmaceuticals Solutions Inc.; 2014 Mar.
66. DEPO-TESTOSTERONE (testosterone cypionate) injection, package insert. New York, NY: Pharmacia & Upjohn Co.; 2006 Sept.
67. Kochenour NK. Lactation suppression. Clin Obstet Gynecol. 1980;23:1045-1059.
68. Testim (testosterone gel) package insert. Malvern, PA: Auxilium Pharmaceuticals, Inc.; 2010 Apr.
69. Axiron (testosterone) topical solution, package insert. Indianapolis, IN: Lilly USA, LLC; 2011 Dec.
70. Androderm (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 2014 Jun.
71. Mudge GH, Weiner IM. Agents affecting volume and composition of body fluids. Gilman AG, Rall TW, Nies AS, Taylor P, (eds.) In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. 8th ed., New York, Pergamon Press. 1990:620, 696—97.
72. Hamilton C. Acid-base disorders Gilman AG, Wells BG, Dipiro JT, Schwinghammer TL, et al. (eds.) In: Pharmacotherapy Handbook. 5th ed., New York, Pergamon Press. 1993:753—61.
73. Mudge GH, Weiner IM. Agents affecting volume and composition of body fluids. Gilman AG, Rall TW, Nies AS, Taylor P, (eds.) In: Goodman and Gilman’s Pharmacological Basis of Therapeutics. 8th ed., New York, Pergamon Press. 1990:620, 696-97.
74. Hamilton C. Acid-base disorders Gilman AG, Wells BG, Dipiro JT, Schwinghammer TL, et al. (eds.) In: Pharmacotherapy Handbook. 5th ed., New York, Pergamon Press. 1993:753-61.
75. Colchicine Tablets, USP package insert. Corona, CA: Watson Laboratories, Inc.; 2001 Jun.
76. Bellward GD, Warren PM, Howald W, et al. Methadone maintenance: effect of urinary pH on renal clearance in chronic high and low doses. Clin Pharmacol Ther 1977;22:92—9.
77. Nilsson M-I, Widerlov E, Meresaar U, et al. Effect of urinary pH on the disposition of methadone in man. Eur J Clin Pharmacol 1982;22:337—42.
78. Wolff K, Rostami-Hodjegan A, Hay AW, et al. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility. Addiction 2000;95:1771—83.
79. Dolophine® (methadone) package insert. Columbus, OH: Roxane Laboratories, Inc; 2006 Oct.
80. Krauser JA, Guengerich FP. Cytochrome P450 3A4-catalyzed testosterone 6beta-hydroxylation stereochemistry, kinetic deuterium isotope effects, and rate-limiting steps. J Biol Chem 2005;280:19496—506.
81. Barnes KM, Dickstein B, Cutler GB Jr, et al. Steroid transport, accumulation, and antagonism of P-glycoprotein in multidrug-resistant cells. Biochemistry 1996;35:4820—7.
82. Wells PS, Holbrook AM, Crowther NR et al. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676—83.
83. Goffin E, Pirson Y, Geubel A, et al. Cyclosporine-methyltestosterone interaction. Nephron 1991;59:174—5.
84. Borras-Blasco J, Rosique-Robles JD, Peris-Marti J, et al. Possible cyclosporin-danazol interaction in a patient with aplastic anaemia. Am J Hematol 1999;62:63—4.
85. Moller BB, Ekelund B. Toxicity of cyclosporine during treatment with androgens. N Engl J Med 1985;313:1416.
86. Ross WB, Roberts D, Griffin PJ, et al. Cyclosporin interaction with danazol and norethisterone. Lancet 1986;1:330.
87. Androgel® (testosterone gel) package insert. Montrogue, France: Laboratories Besins International; 2005 Aug.
88. Zoladex® (goserelin acetate) package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2003 Dec.
89. Viadur® (leuprolide implant) package insert. Westhaven, CT: Bayer Pharmaceuticals; 2002 May.
90. Humatrope™ (somatropin);package insert. Indianapolis, IN: Eli Lilly and Company; 2003 Jul.
91. Androderm® (testosterone transdermal system) package insert. Corona, CA: Watson Pharma, Inc.; 1999 Jan.
92. Propecia® (finasteride) package insert. Whitehouse Station, NJ: Merck & Co., INC.; 2003 Oct.
93. Avodart™ (dutasteride) package insert. Research Triangle Park, NC: GlaxoSmithKline; 2005 May.
94. Robbers JE, Tyler VE. Tyler’s Herbs of Choice: the Therapeutic Use of Phytomedicinals. Binghamton NY: Haworth Herbal Press, Inc.; 1999.
95. German Commission E. Saw Palmetto berry, Sabal fructus, monograph Published March 2, 1989 and revised January 17, 1991. In: Blumenthal, M et al ., eds. The complete German Commission E Monographs -Therapeutic Guide to Alternative Medicines. Bosto
96. Lazar JD, Wilner KD. Drug interactions with fluconazole. Rev Infect Dis 1990;12:S327—33.
97. Hansten P, Horn J. The Top 100 Drug Interactions: A Guide to Patient Management. includes table of CYP450 and drug transporter substrates and modifiers (appendices). H & H Publications, LLP 2014 edition.
98. Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity, and partial androgen deficiency. Aging Male 2003;6:1—7.
99. Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity, and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Clin Endocrinol 2006; 154:899—90
100. Hobbs CJ, Jones RE, Plymate SR. Nandrolone, a 19-nortestosterone, enhances insulin-independent glucose uptake in normal men. J Clin Endocrinol Metab 1996; 81:1582—5.
101. Corrales JJ, Burgo RM, Garcia-Berrocal B, et al. Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control. Metabolism 2004;53:666—72
102. Lee CH, Kuo SW, Hung YJ, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocrine Res 2005;31:139—148.
103. Cohen JC, Hickman R. Insulin resistance and diminished glucose tolerance in powerlifters ingesting anabolic steroids. J Clin Endocrinol Metab 1987;64:960—3.
104. Aldercreutz H, Mazur W. Phyto-estrogens and western diseases. Annals of Medicine 1997;29:95—120.
105. Ranexa (ranolazine extended-release tablets) package insert. Foster City, CA: Gilead Sciences, Inc. 2013 Dec.
106. Letairis™ (ambrisentan) package insert. Foster City, CA: Gilead Sciences, Inc; 2008 Oct.
107. Pradaxa (dabigatran) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2015 Jan.
108. Gilotrif (afatinib) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2013 Nov.
109. Theo-24 (theophylline, anhydrous) package insert. Malvern, PA: Endo Pharmaceuticals, Inc.; 2019 Mar.
110. Olson KR, Benowitz NL, Woo OF, et al. Theophylline overdose: Acute single ingestion versus chronic repeated overmedication. Am J Emerg Med 1985;3:386-94.
111. Shannon M. Predictors of major toxicity after theophylline overdose. Ann Intern Med 1993;119:1161-7.
112. Nutrient-Drug Interactions and Drug-Induced Nutrient Depletions. In: Stargrove MB, Treasure J, McKee DL. Herb, Nutrient, and Drug Interactions: Clinical Implications and Therapeutic Strategies. St. Louis: Mosby Elsevier; 2008:173-831.
113. Trental (pentoxifylline) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals Inc.; 2010 Jun.
114. Batshaw, ML, MacArthur RB, Tuchman M. Alternative pathway therapy for urea cycle disorders: twenty years later. J Pediatr 2001; 138:S46 S55
115. Androgel 1.62% (testosterone gel) package insert. North Chicago, IL: Abbott Laboratories; 2014 Nov.
116. Naik BS, Shetty N, Maben EVS. Drug-induced taste disorders. European Journal of Internal Medicine 2010; 21:240-243.